Relay Therapeutics (RLAY) Operating Leases (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Operating Leases data on file, last reported at $27.7 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 32.87% year-over-year to $27.7 million in Q1 2026; TTM through Mar 2026 was $27.7 million, a 32.87% decrease from a year earlier, with the FY2025 full-year figure at $28.7 million, down 32.92% from the prior year.
• Operating Leases for Q1 2026 stood at $27.7 million, down from $28.7 million in the prior quarter.
• Over the last five years, Operating Leases for RLAY reached as high as $54.6 million in Q3 2022 and fell as low as $20.0 million in Q2 2022.
• Historically, Operating Leases has averaged $40.5 million across 5 years, with a median of $44.3 million in 2024.
• Across the five-year window, Operating Leases surged 155.25% in 2023 and slumped 33.01% in 2025, its largest moves.
• Year by year, Operating Leases stood at $53.5 million in 2022, then decreased by 9.28% to $48.5 million in 2023, then declined by 11.81% to $42.8 million in 2024, then plunged by 32.92% to $28.7 million in 2025, then dropped by 3.53% to $27.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $27.7 million in Q1 2026, $28.7 million in Q4 2025, and $29.7 million in Q3 2025.